Advanced Search

Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 1999 January-February;51(1-2) > Minerva Ginecologica 1999 January-February;51(1-2):15-8



A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Frequency: Bi-Monthly

ISSN 0026-4784

Online ISSN 1827-1650


Minerva Ginecologica 1999 January-February;51(1-2):15-8


Ultrasonographic monitoring as a method of preventing the risks of ovarian hyperstimulation during pharmacological treatment

Grio R., Patriarca A., Ramondini L., Ferrara L., Curti A., Piacentino R.

Background and aims. Ultrasonographic monitoring represents the most immediate method for an early confirmation of the onset of the worst complication of the pharmacological induction of ovulation: ovarian hyperstimulation. The aim of this study was to evaluate the incidence of this complication in a sample group of anovulatory patients receiving pharmacological treatment and undergoing repeated ultrasonographic monitoring.
Methods. The authors analysed the controls performed during 1996-1997 in which a total of 413 cycles were stimulated. The patients included in the study group (mean age 28.5 years) were treated using clomiphene, oestradiol, FSH, LH and GnRH, and in 5 cases stimulation was preceded by suppression of the menstrual cycle using tryptorelin. Each patient was monitored with 3 scans, except for those treated with tryptorelin or GnRH who were more closely monitored.
Results. In 413 patients included in this study the authors noted the onset of slight hyperstimulation in 6 cases (1.45%) which then resolved spontaneously without the need for hospitalisation.
Conclusions. The authors affirm that ultrasonographic monitoring represents a valid means of controlling and preventing the risks of ovarian hyperstimulation.

language: Italian


top of page